Toll-like receptor 3 signaling induces apoptosis in human head and neck cancer via survivin associated pathway

Nomi, Nozomi; Kodama, Satoru; Suzuki, Masashi

doi:10.3892/or_00000850

Cited by 16 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TLR3 may contribute to tumor development and lead to cisplatin resistance in OC2 cells (54). However, in 8 other head and neck cancer cell lines (HEp2, SCC25, HSC2, HSC3, HSC4, SAS, HSQ89 and HO-1-u-1), poly (I:C)-stimulated TLR3 induced apoptosis in these cell lines though downregulating survivin expression (55). In addition, in the OSCC cell lines HB, CAL27 and WSU-HN6, poly (I:C) induced apoptosis via TLR3 though the production of IFN-b and activation of caspase 3 and 9 (56).…”

Section: Head and Neck Cancersmentioning

confidence: 97%

Roles of Toll-Like Receptor 3 in Human Tumors

Zheng¹,

Li²,

Yang³

2021

Front. Immunol.

View full text Add to dashboard Cite

Toll-like receptor 3 (TLR3) is an important member of the TLR family, which is an important group of pathogen-associated molecular patterns. TLR3 can recognize double-stranded RNA and induce activation of NF-κB and the production of type I interferons. In addition to its immune-associated role, TLR3 has also been detected in some tumors. However TLR3 can play protumor or antitumor roles in different tumors or cell lines. Here, we review the basic signaling associated with TLR3 and the pro- or antitumor roles of TLR3 in different types of tumors and discuss the possible reasons for the opposing roles of TLR3 in tumors.

show abstract

Section: Head and Neck Cancersmentioning

confidence: 97%

Roles of Toll-Like Receptor 3 in Human Tumors

Zheng¹,

Li²,

Yang³

2021

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…356 Stimulation of TLR3 in tumor cells derived from human head and neck cancer has also been found to downregulate the anti-apoptotic protein survivin. 357 Additionally, both TLR4 and TLR7 have been implicated in the direct induction of cellular apoptosis. In acute monocytic leukemia, malignant monocytic cells undergo apoptosis in a TLR4-dependent manner.…”

Section: Innate Immune Pathways In Cancermentioning

confidence: 99%

Harnessing innate immune pathways for therapeutic advancement in cancer

Hu,

Sun,

Lin

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

The innate immune pathway is receiving increasing attention in cancer therapy. This pathway is ubiquitous across various cell types, not only in innate immune cells but also in adaptive immune cells, tumor cells, and stromal cells. Agonists targeting the innate immune pathway have shown profound changes in the tumor microenvironment (TME) and improved tumor prognosis in preclinical studies. However, to date, the clinical success of drugs targeting the innate immune pathway remains limited. Interestingly, recent studies have shown that activation of the innate immune pathway can paradoxically promote tumor progression. The uncertainty surrounding the therapeutic effectiveness of targeted drugs for the innate immune pathway is a critical issue that needs immediate investigation. In this review, we observe that the role of the innate immune pathway demonstrates heterogeneity, linked to the tumor development stage, pathway status, and specific cell types. We propose that within the TME, the innate immune pathway exhibits multidimensional diversity. This diversity is fundamentally rooted in cellular heterogeneity and is manifested as a variety of signaling networks. The pro-tumor effect of innate immune pathway activation essentially reflects the suppression of classical pathways and the activation of potential pro-tumor alternative pathways. Refining our understanding of the tumor’s innate immune pathway network and employing appropriate targeting strategies can enhance our ability to harness the anti-tumor potential of the innate immune pathway and ultimately bridge the gap from preclinical to clinical application.

show abstract

“… 202 In contrast to the above findings, TLR3 activation induced an increase of inflammatory cytokines that suppressed cell proliferation, directly induced cell death, and reduced migration of cells in OSCC. 203 , 204 , 205 , 206 The different results of TLR3 agonists in OSCC may be related to differences in cell types or in the concentrations of the TLR3 agonists used. Therefore, the use of TLR3 agonists in OSCC remains to be evaluated.…”

Section: Tlr‐related Diseasesmentioning

confidence: 99%

Toll‐like receptors in health and disease

Wang,

Huang,

Zhan

et al. 2024

MedComm

View full text Add to dashboard Cite

Toll‐like receptors (TLRs) are inflammatory triggers and belong to a family of pattern recognition receptors (PRRs) that are central to the regulation of host protective adaptive immune responses. Activation of TLRs in innate immune myeloid cells directs lymphocytes to produce the most appropriate effector responses to eliminate infection and maintain homeostasis of the body's internal environment. Inappropriate TLR stimulation can lead to the development of general autoimmune diseases as well as chronic and acute inflammation, and even cancer. Therefore, TLRs are expected to be targets for therapeutic treatment of inflammation‐related diseases, autoimmune diseases, microbial infections, and human cancers. This review summarizes the recent discoveries in the molecular and structural biology of TLRs. The role of different TLR signaling pathways in inflammatory diseases, autoimmune diseases such as diabetes, cardiovascular diseases, respiratory diseases, digestive diseases, and even cancers (oral, gastric, breast, colorectal) is highlighted and summarizes new drugs and related clinical treatments in clinical trials, providing an overview of the potential and prospects of TLRs for the treatment of TLR‐related diseases.

show abstract

Toll-like receptor 3 signaling induces apoptosis in human head and neck cancer via survivin associated pathway

Cited by 16 publications

References 21 publications

Roles of Toll-Like Receptor 3 in Human Tumors

Roles of Toll-Like Receptor 3 in Human Tumors

Harnessing innate immune pathways for therapeutic advancement in cancer

Toll‐like receptors in health and disease

Contact Info

Product

Resources

About